Promising new therapies for cardiovascular disease are changing patient care and how it’s delivered. These include a new class of drugs, PCSK9 inhibitors, which provide a powerful alternative to the stand-alone use of statins in reducing high cholesterol.
PCSK9 therapy is helpful for people diagnosed with plaque-related heart or blood vessel problems (atherosclerotic heart disease) or inherited high LDL (heterozygous familial hypercholesterolemia, HeFH), who can’t take statins or need to reduce LDL cholesterol beyond what statin therapy can do.
Examples of atherosclerotic disease include:
- Heart attack (myocardial infarction)
- Stable or unstable angina (cardiac chest pain)
- Heart bypass surgery or stent placement
- Transient ischemic attack
- Artery blockage
But new medications like PCSK9 inhibitors can pose new challenges. Whether it’s navigating the prior authorization process, understanding requirements for lab work, or helping patients and their healthcare providers manage the administration of injectable drugs, Apothecary By Design does what it takes to help make the most of today’s cardiovascular medicines.
To reduce the financial burden of these medicines, we are experts at helping patients optimize their insurance benefits and at securing additional financial assistance.
For example, the ABD team understands the complexities of Medicare and its “donut hole” in coverage, and we routinely access funding from manufacturers, nonprofit organizations, and other sources to minimize this burden. As a result, many of our patients with cardiovascular disease see their copayments reduced to just a few dollars.